Stockscreener 앱 받기
4.89
0.20%
0.010
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
What is HC Wainwright's Forecast for FHTX FY2026 Earnings? - MarketBeat
Foghorn Therapeutics’ (FHTX) Outperform Rating Reiterated at Wedbush - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
FY2030 Earnings Estimate for FHTX Issued By HC Wainwright - Defense World
Brokers Offer Predictions for FHTX FY2030 Earnings - MarketBeat
Foghorn Therapeutics (FHTX) Receives a Buy from Guggenheim - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), RegenXBio (RGNX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
Foghorn Therapeutics (FHTX) FY 2025 Losses Reinforce Bearish Unprofitability Narrative - Sahm
Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data - Investing.com Australia
Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data By Investing.com - Investing.com South Africa
Foghorn Therapeutics reports $158.9M cash position, extends runway - Investing.com Australia
Foghorn Therapeutics (NASDAQ:FHTX) Earns "Outperform" Rating from Wedbush - MarketBeat
Stifel reiterates Foghorn Therapeutics stock rating at buy By Investing.com - Investing.com India
Stifel reiterates Foghorn Therapeutics stock rating at buy - Investing.com
Foghorn Therapeutics: Pioneering Precision Oncology with Chromatin Regulatory System Targeting and Gene Traffic Control Platform - Minichart
Foghorn Advances FHD-909 Trial and Strengthens Financial Position - TipRanks
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook - Bitget
Foghorn Therapeutics Inc. (FHTX) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Foghorn Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Foghorn Therapeutics 10-K: $30.9M revenue, $(1.18) EPS - TradingView
Foghorn Therapeutics (NASDAQ:FHTX) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Foghorn Therapeutics (FHTX) maps chromatin-targeting cancer pipeline with Lilly - Stock Titan
Foghorn Therapeutics (NASDAQ: FHTX) narrows 2025 loss and extends cash runway into 2028 - Stock Titan
Cancer drug developer Foghorn raises $50M, funds work on hard-to-treat tumors - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Given Buy Rating at HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Foghorn Therapeutics (NASDAQ:FHTX) - MarketBeat
HC Wainwright Reiterates Buy Rating for Foghorn Therapeutics (FH - GuruFocus
Aug Volume: Is Foghorn Therapeutics Inc part of any major index2026 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates - MSN
Will Foghorn Therapeutics Inc. stock benefit from AI adoptionForecast Cut & Smart Investment Allocation Insights - Naître et grandir
Foghorn Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
FHTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TD Cowen Health Care Conference - marketscreener.com
Should you avoid Foghorn Therapeutics Inc. stock right nowJuly 2025 Volume & Short-Term Trading Alerts - mfd.ru
Foghorn Therapeutics (FHTX) Projected to Post Earnings on Thursday - Defense World
Foghorn Therapeutics (FHTX) grants CFO 400,000 stock options - Stock Titan
Foghorn Therapeutics (FHTX) CFO files Form 3 insider ownership - Stock Titan
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - Investing News Network
Foghorn Therapeutics names Ryan Maynard as chief financial officer By Investing.com - Investing.com India
Foghorn Therapeutics Names Veteran Executive as New CFO - The Globe and Mail
FHTXFoghorn Therapeutics Inc. Latest Stock News & Market Updates - Stock Titan
Foghorn Therapeutics names Ryan Maynard as chief financial officer - Investing.com
Foghorn Therapeutics (FHTX) Appoints New CFO with Extensive Expe - GuruFocus
Foghorn Therapeutics Appoints Ryan Maynard CFO - marketscreener.com
Foghorn Therapeutics Inc. Appoints Ryan Maynard as Chief Financial Officer - Quiver Quantitative
Ryan Maynard joins Foghorn Therapeutics (NASDAQ: FHTX) as new CFO - Stock Titan
Foghorn Therapeutics Inc. Announces Executive Changes - marketscreener.com
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know - MSN
1.20%
0.06%
자본화:
|
볼륨(24시간):